Gilead(US:GILD) ZACKSยท2025-09-25 23:01Company Performance - Gilead Sciences (GILD) closed at $110.99, reflecting a -2.36% change from the previous day, underperforming the S&P 500's daily loss of 0.5% [1] - Over the past month, Gilead's shares have decreased by 0.22%, outperforming the Medical sector's loss of 0.7% but lagging behind the S&P 500's gain of 2.74% [1] Upcoming Earnings - Analysts expect Gilead to report an EPS of $2.15, a 6.44% increase compared to the same quarter last year, with a projected quarterly revenue of $7.43 billion, down 1.59% from the previous year [2] - For the annual period, earnings are anticipated to be $8.08 per share and revenue at $28.75 billion, indicating a +74.89% change in earnings and no change in revenue from last year [3] Analyst Revisions and Rankings - Recent revisions to analyst forecasts are crucial as they reflect near-term business trends, with positive revisions indicating confidence in Gilead's performance [3] - Gilead currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 0.22% over the last 30 days [5] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 14.06, which is lower than the industry average of 19.43, suggesting it is trading at a discount [6] - The company has a PEG ratio of 0.77, compared to the industry average of 1.72, indicating a favorable valuation relative to expected earnings growth [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [8]